The BIOKÉ webshop is closed until January 2nd, 2019. We wish you a successful 2019!
LEIDEN, March 22, 2017 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s xCELLigence® Cell Analyzer in the BeNeLux countries (Netherlands, Belgium, Luxembourg), effective immediately.
The xCELLigence Real-Time Cell Analysis (RTCA) systems maximize the physiological relevance of data extracted from in vitro cellular assays by enabling label-free, real-time monitoring of cell attachment quality, cell proliferation, and cell invasion/migration by employing a micro sensor arrays integrated into the bottom of each wells of plates (E-Plates). By continuously providing this data in the short (minutes to hours) and long (days to weeks) time regimes, RTCA provides a phenotypic view of cellular behavior at an unprecedented level of detail. The xCELLigence System offers a variety of format options to meet a broad range of application and throughput needs.
Founded in 2004, BIOKÉ is an experienced and knowledgeable company that provides innovative products with the highest quality in the life science industry throughout Europe. BIOKÉ delivers unique and high-performance applications and workflows for genomics, protein analysis and cell biology. Since July 2009 BIOKÉ is the official EMEA base of operations for Cell Signaling Technology (CST), the market leader in the development of high quality antibody products and technologies. For additional information please visit the BIOKÉ website at www.bioke.com
About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. ACEA’s xCELLigence impedance-based, label-free, real-time cell analysis instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,000 instruments have been placed globally, leading to >1,200 peer reviewed publications. Visit www.aceabio.com to learn more.